AP3250A - Tablets for combination therapy - Google Patents

Tablets for combination therapy

Info

Publication number
AP3250A
AP3250A AP2011005857A AP2011005857A AP3250A AP 3250 A AP3250 A AP 3250A AP 2011005857 A AP2011005857 A AP 2011005857A AP 2011005857 A AP2011005857 A AP 2011005857A AP 3250 A AP3250 A AP 3250A
Authority
AP
ARIPO
Prior art keywords
tablets
combination therapy
therapy
combination
Prior art date
Application number
AP2011005857A
Other languages
English (en)
Other versions
AP2011005857A0 (en
Inventor
Joanna M Koziara
Reza Oliyal
Mark M Menning
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2011005857A0 publication Critical patent/AP2011005857A0/xx
Application granted granted Critical
Publication of AP3250A publication Critical patent/AP3250A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2011005857A 2009-02-06 2010-02-04 Tablets for combination therapy AP3250A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06
PCT/US2010/023226 WO2010091197A2 (en) 2009-02-06 2010-02-04 Tablets for combination therapy

Publications (2)

Publication Number Publication Date
AP2011005857A0 AP2011005857A0 (en) 2011-10-31
AP3250A true AP3250A (en) 2015-05-31

Family

ID=41722740

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005857A AP3250A (en) 2009-02-06 2010-02-04 Tablets for combination therapy

Country Status (31)

Country Link
US (2) US20100285122A1 (es)
EP (1) EP2393485B1 (es)
JP (2) JP5611242B2 (es)
KR (2) KR101738325B1 (es)
CN (1) CN102307573B (es)
AP (1) AP3250A (es)
AR (1) AR075369A1 (es)
AU (1) AU2010210598B2 (es)
BR (1) BRPI1008664A2 (es)
CA (1) CA2750521A1 (es)
CL (1) CL2011001885A1 (es)
CY (1) CY1116852T1 (es)
DK (1) DK2393485T3 (es)
EA (2) EA030123B1 (es)
EC (1) ECSP11011307A (es)
ES (1) ES2548886T3 (es)
HK (1) HK1164737A1 (es)
HR (1) HRP20151009T1 (es)
HU (1) HUE025822T2 (es)
IL (1) IL214227A (es)
MX (1) MX2011008289A (es)
NZ (1) NZ594214A (es)
PE (1) PE20110994A1 (es)
PL (1) PL2393485T3 (es)
PT (1) PT2393485E (es)
SG (3) SG173544A1 (es)
SI (1) SI2393485T1 (es)
SM (1) SMT201500266B (es)
TW (1) TWI444367B (es)
UY (1) UY32424A (es)
WO (1) WO2010091197A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ573060A (en) 2006-07-07 2012-02-24 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
HUE029842T2 (en) * 2007-02-23 2017-04-28 Gilead Sciences Inc Modulation of pharmacokinetic parameters of therapeutic agents
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
SG190333A1 (en) 2010-11-19 2013-06-28 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
US20130243833A1 (en) * 2010-11-29 2013-09-19 Formac Pharmaceuticals N.V. Compressed formulations of ordered mesoporous silicas
EP2729130B1 (en) 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations
HUE031253T2 (en) 2011-08-16 2017-07-28 Gilead Sciences Inc Tenofovir alafenamid hemifumarate
JP6059255B2 (ja) * 2012-02-03 2017-01-11 ギリアード サイエンシス インコーポレーテッド ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法
AU2012327170A1 (en) * 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
CA2865491A1 (en) * 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
CN103830192A (zh) * 2012-11-27 2014-06-04 安徽贝克生物制药有限公司 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
KR102406288B1 (ko) 2012-12-21 2022-06-13 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CA2990210C (en) 2015-06-30 2021-01-12 Gilead Sciences, Inc. Pharmaceutical formulations comprising tenofovir and emtricitabine
KR20240095320A (ko) 2015-11-09 2024-06-25 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
ES2806604T3 (es) 2016-02-02 2021-02-18 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176220B2 (en) * 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE10153078A1 (de) * 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
CN100375742C (zh) * 2002-11-20 2008-03-19 日本烟草产业株式会社 4-氧代喹啉化合物及其用途
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AP2008004533A0 (en) * 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
NZ573060A (en) * 2006-07-07 2012-02-24 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176220B2 (en) * 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
WO2008103949A1 (en) * 2007-02-23 2008-08-28 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FOR THE UK COLLABORATIVE HIV COHORT (CHIC) STUDY PHILLIPS ET AL.: "Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 370, no. 9603, 6 December 2007 (2007-12-06), pages 1923-1928, XP022379072, ISSN: 0140-6736, the whole document *
GERMAN P. ET AL.: "pharmacokinetics and bioavailability of an integrate and novel pharmacoenhancer-containing single tablet ixed dose combination", JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, LIPPINCOTT WILLIAMS AND WILKINS, PHILADELPHIA, PA, US, vol. 55, no. 3, 1 November 2010 (2010-11-01), pages 323-329, XP008134624, ISSN: 1525-4135, the whole document *
J. MARTINEZ-CAJAS ET AL.: "Antiretroviral therapy- Optimal sequencing of therapy to avoid resistance", DRUGS, vol. 68, no. 1, 2008, pages 43-72, XP8134919, the whole document *
L. SZCZECH: "Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context", THE JOURNAL OF INFECTIOUS DISEASES, vol. 197, no. 1, 2008, pages 7-9, XP002630507, the whole document *
S. HAMMER ET AL.: "Antiretroviral treatment of adult HIV infection. 2008 Recommendations of the International AIDS Society- USA panel.", JAMA, THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 300, no. 5, 2008, pages 555-570, XP8134902, the whole document *
V. VON WYL ET AL.: "Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment", ARCHIVES OF INTERNAL MEDICINE, vol. 167, no. 16, 2007, pages 1782-1790, XP002630508, the whole document *

Also Published As

Publication number Publication date
CY1116852T1 (el) 2017-04-05
DK2393485T3 (en) 2015-10-26
ECSP11011307A (es) 2011-10-31
PE20110994A1 (es) 2012-01-24
AR075369A1 (es) 2011-03-30
EA021313B1 (ru) 2015-05-29
EA201190125A1 (ru) 2012-01-30
EA201491658A1 (ru) 2015-05-29
HUE025822T2 (en) 2016-04-28
HRP20151009T1 (hr) 2015-10-23
TWI444367B (zh) 2014-07-11
MX2011008289A (es) 2011-09-15
EP2393485B1 (en) 2015-07-29
NZ594214A (en) 2013-05-31
KR101645759B1 (ko) 2016-08-04
IL214227A0 (en) 2011-09-27
SI2393485T1 (sl) 2015-10-30
UY32424A (es) 2010-09-30
ES2548886T3 (es) 2015-10-21
JP5611242B2 (ja) 2014-10-22
KR101738325B1 (ko) 2017-05-19
CN102307573B (zh) 2013-09-11
KR20160093100A (ko) 2016-08-05
SMT201500266B (it) 2016-01-08
SG2014007744A (en) 2014-05-29
TW201040142A (en) 2010-11-16
EP2393485A2 (en) 2011-12-14
US20100285122A1 (en) 2010-11-11
WO2010091197A3 (en) 2011-06-03
JP5911927B2 (ja) 2016-04-27
US20150150810A1 (en) 2015-06-04
AU2010210598A1 (en) 2011-08-25
WO2010091197A2 (en) 2010-08-12
AU2010210598B2 (en) 2015-03-05
CA2750521A1 (en) 2010-08-12
AP2011005857A0 (en) 2011-10-31
SG10201706215UA (en) 2017-08-30
EA030123B1 (ru) 2018-06-29
CL2011001885A1 (es) 2012-05-25
HK1164737A1 (en) 2012-09-28
SG173544A1 (en) 2011-09-29
PT2393485E (pt) 2015-10-23
CN102307573A (zh) 2012-01-04
IL214227A (en) 2017-01-31
JP2014221845A (ja) 2014-11-27
PL2393485T3 (pl) 2015-12-31
KR20110122729A (ko) 2011-11-10
BRPI1008664A2 (pt) 2016-03-08
JP2012517432A (ja) 2012-08-02

Similar Documents

Publication Publication Date Title
AP3250A (en) Tablets for combination therapy
GB0916335D0 (en) Medicaments
GB0909680D0 (en) Dosage form
ZA201200761B (en) Tablet
EP2427183A4 (en) THERAPEUTIC COMPOUNDS
GB0922589D0 (en) Pharmaceutical compounds
AU330360S (en) Tablet
GB0920041D0 (en) Tablet
GB0900484D0 (en) Therapeutic agent
EP2496704A4 (en) THERAPEUTIC COMPOUNDS
GB0915319D0 (en) Combination medicament
GB0916997D0 (en) Combination therapy
GB0908905D0 (en) Pharmaceutical compounds
GB0916332D0 (en) Medicaments
EP2456309A4 (en) THERAPEUTIC COMPOUNDS
GB0906026D0 (en) Therapeutic compounds
GB0907973D0 (en) Combination therapy
GB0916308D0 (en) Therapeutic compounds
GB0900712D0 (en) Therapeutic compounds
GB0911266D0 (en) Therapeutic compounds
GB0916608D0 (en) Therapeutic compounds
GB0914820D0 (en) WATerian therapy
GB0921244D0 (en) Therapy
GB0903319D0 (en) Therapy
GB0903321D0 (en) Therapy